Pharmacokinetics of gadoversetamide injection, a gadolinium-based contrast agent, in pediatric patients

Abstract Objective The pharmacokinetics of gadoversetamide were examined in pediatric patients scheduled to undergo contrast-enhanced MRI of the central nervous system. Materials and Methods One hundred patients received an intravenous injection of gadoversetamide at a dose of 0.1 mmol/kg for a contrast-enhanced MRI procedure. A subpopulation of 30 patients were enrolled to evaluate the pharmacokinetics of gadoversetamide in patients 2–11 and 12–18 years of age. Serial blood and urine samples were collected before and after the administration of gadoversetamide. Results The terminal half-life, initial concentration and area under the curve assessments for gadoversetamide showed no significant ( P >.05) differences between the age groups or the sexes. Although no sex-related differences occurred in the volume of distribution or clearance, significant ( P